Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].

Core Viewpoint - Tong Ren Tang Technologies (01666.HK) announced the appointment of Xiao Yao Xi as an independent non-executive director of the company, effective from February 6, 2026, while Li Zhao Bin will resign from the same position on the same date [1] Group 1 - Li Zhao Bin's resignation as the chairman of the Audit Committee, as well as a member of the Remuneration Committee and the Strategy and Planning Committee, will also take effect on February 6, 2026 [1] - The board has resolved to appoint Xiao Yao Xi as the chairman of the Audit Committee, and as a member of the Remuneration Committee and the Strategy and Planning Committee, with all appointments effective on the same date [1]

Core Viewpoint - Tongrentang Technology (01666) announced the appointment of Mr. Xiao Yaoxi as an independent non-executive director of the company’s ninth board of directors, effective from February 6, 2026, while Mr. Li Zhaobin will resign from the position of independent non-executive director on the same date [1] Group 1 - Mr. Li Zhaobin's resignation as chairman of the audit committee, as well as a member of the remuneration committee and the strategic and planning committee, will also take effect on February 6, 2026 [1] - The board has resolved to appoint Mr. Xiao Yaoxi as the chairman of the audit committee, as well as a member of the remuneration committee and the strategic and planning committee, with all appointments effective on the same date [1]

Core Viewpoint - Tongrentang Medical Investment Co., Ltd. is making another attempt to go public on the Hong Kong Stock Exchange after multiple delays since its initial filing in June 2024, despite having turned a profit in 2023 [1] Group 1: IPO Progress and Financial Performance - The company submitted its prospectus for the fourth time, indicating ongoing efforts to secure an IPO [1] - In the first three quarters of 2025, the company reported revenue of approximately 858 million yuan, a year-on-year increase of about 3%, while net profit decreased by 9.8% to around 24 million yuan [1][3] - The revenue growth rate has slowed significantly, dropping from approximately 26.56% in 2023 to less than 2% in 2024, with only about 3% growth in the first three quarters of 2025 [3] Group 2: Business Operations and Acquisitions - Tongrentang Medical's main business includes traditional Chinese medical services, management services, and health product sales [3] - The company has made several acquisitions, contributing significantly to its revenue, with total contributions of approximately 2 billion yuan, 3.61 billion yuan, 4.78 billion yuan, and 3.52 billion yuan from 2022 to the first three quarters of 2025, accounting for 22.1%, 31.3%, 40.7%, and 41% of total revenue respectively [4] - The company sold its stake in Shijiazhuang Tongrentang Traditional Chinese Medicine Hospital for approximately 17.1 million yuan in August 2024, which impacted net profit figures when excluding this one-time gain [4] Group 3: Profitability and Cost Structure - The net profit margin decreased from 3.2% in the first three quarters of 2024 to 2.8% in 2025, indicating declining profitability despite previous asset sales [5] - The cost of sales has been rising, with the cost of drugs and medical supplies consistently accounting for over 54% of total costs [5][6] - Employee welfare expenses have also increased, amounting to approximately 183 million yuan in the first three quarters of 2025, representing 22.6% of total costs [5][6] Group 4: Financial Health and Cash Flow - As of September 30, 2025, the company's cash and cash equivalents were approximately 225 million yuan, a decrease of about 71 million yuan from the end of 2024 [6] - The company has pledged significant equity stakes in its subsidiaries to secure bank financing, indicating reliance on external funding for capital expenditures and operational needs [6] - The asset-liability ratio increased from 39.7% in 2022 to 46.6% by September 30, 2025, reflecting a growing financial burden [7]

Core Viewpoint - Tongrentang Technology has successfully launched its key cardiovascular drug, the Kuanxiong Aerosol, which has entered the production phase, reflecting the company's commitment to innovation in modern pharmaceutical technology [1][4]. Group 1: Product Development - The Kuanxiong Aerosol is developed based on traditional Chinese medicine theories, targeting the root causes of cardiovascular diseases such as coronary heart disease and angina [3]. - The aerosol employs an innovative sublingual spray delivery method, allowing active ingredients to be rapidly absorbed into the bloodstream, enhancing the drug's efficacy [4]. - The production process incorporates advanced technology to improve drug stability and minimize the degradation of active components, ensuring consistent therapeutic effects [4]. Group 2: Market Position and Future Plans - Tongrentang Technology currently offers over 20 types of cardiovascular medications, including Guanxin Suhe Pills and Compound Danshen Tablets, focusing on the growing demand for cardiovascular treatments [4]. - The company is accelerating the development of its innovative traditional Chinese medicine, Qishen Granules, aimed at treating chronic heart failure, which has successfully completed Phase II clinical trials [4].

Core Viewpoint - The Chinese traditional medicine sector is experiencing a significant boost due to favorable policies, leading to a strong market performance and increased trading volume in related ETFs and stocks [1][5]. Policy Developments - On February 5, eight departments jointly issued the "Implementation Plan for the High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)," outlining goals and measures for the next five years to enhance the entire industry chain [5]. - The plan aims to establish a collaborative development system for the traditional Chinese medicine industry by 2030, focusing on stable supply of key raw materials, technological breakthroughs, and the cultivation of leading enterprises [5]. Market Performance - The leading traditional Chinese medicine ETF (560080) opened with a jump of over 2%, marking a strong upward trend with significant trading volume exceeding 160 million yuan within the first 20 minutes of trading [1]. - Notable stocks in the sector include Longshen Rongfa, Shanghai Kaibao, and Panlong Pharmaceutical, which saw increases of over 6%, while Hongri Pharmaceutical and Yiling Pharmaceutical rose by over 5% and 4%, respectively [2][3]. Investment Opportunities - Pacific Securities highlights the rapid growth of the traditional Chinese medicine market, driven by comprehensive policy support across various aspects, including registration, quality control, and cultural promotion [6]. - The sector is expected to benefit from a recovery in consumer demand, particularly due to aging demographics and increased health awareness, which will drive sales of consumer-oriented traditional Chinese medicine products [8]. Strategic Focus Areas - Three main investment themes are identified: 1. Price governance, focusing on companies with competitive advantages that can benefit from price reductions [8]. 2. Consumption recovery, driven by macroeconomic improvement and increased domestic demand [10]. 3. State-owned enterprise reform, which presents opportunities for performance improvement through efficiency gains [10]. Future Outlook - The traditional Chinese medicine industry is anticipated to undergo a reshuffling, with a focus on classic formulations and evidence-based medicine, positioning leading companies favorably for future growth [7].

Core Insights - The Jilin Provincial Public Resource Trading Center has initiated a price verification for 48 drugs with significantly higher listed prices compared to retail channels, marking a significant step in addressing the issue of hospital prices exceeding those in pharmacies [2][14] - The price discrepancies range from 1.3 times to 5.2 times, with notable examples including the inhaled budesonide suspension showing a 5.2 times difference and the An Gong Niu Huang Wan from Shandong Hongjitang and Beijing Tongrentang exceeding 4 times [2][15] - This initiative reflects a broader trend in drug price governance, indicating a shift from centralized procurement to comprehensive price management across all channels by 2026 [2][9] Price Discrepancy Details - The inhaled budesonide suspension has a procurement price of 388.11 yuan per mg in medical institutions, while the retail price is only 75 yuan, resulting in a 5.2 times price difference [3][15] - An Gong Niu Huang Wan produced by Shandong Hongjitang has a procurement price of 434.9 yuan per unit, compared to a retail price of 99 yuan, leading to a 4.4 times difference [7] - The price verification process is based on the "mode price," which reflects the most frequently occurring price after excluding outliers, ensuring a fair assessment of market prices [7][8] Industry Context - The rapid development of retail pharmacies and online drug purchasing platforms has intensified price competition, yet procurement prices in medical institutions remain high, exacerbating the price gap [2][8] - The National Medical Insurance Administration's upcoming initiatives, including monitoring online drug prices, aim to address these discrepancies and enhance price transparency [8][9] - The Jilin province's actions are part of a larger national strategy to improve drug pricing systems, with expectations for similar initiatives to be adopted by other provinces in the near future [12][14]

Core Viewpoint - Recently, Jiasitang announced that on February 2, 2026, its shareholders, Everbright Industrial and Everbright Health, signed a share transfer agreement with Beijing Tongrentang (Group) Co., Ltd. This transaction will result in a change of controlling shareholder to Tongrentang Group and the actual controller to the State-owned Assets Supervision and Administration Commission of the People's Government of Beijing Municipality [1] Group 1 - Everbright Industrial and Everbright Health will transfer 41,180,805 shares and 41,876,431 shares, respectively, to Tongrentang Group [1] - Following the completion of this transaction, the controlling shareholder of Jiasitang will change to Tongrentang Group [1] - The actual controller will be the State-owned Assets Supervision and Administration Commission of the People's Government of Beijing Municipality [1]

Core Viewpoint - The Chinese medicine ETF (560080) has shown positive performance with most constituent stocks rising, indicating a favorable market sentiment towards the Chinese medicine sector [1][6]. Group 1: Stock Performance - Major stocks in the Chinese medicine ETF have seen significant gains, with Da Ren Tang rising over 4%, Pian Zai Huang over 3%, and Tong Ren Tang over 2% [1]. - The estimated weights and performance of key stocks include: - Yunnan Baiyao at 10.56% with a 1.47% increase - Pian Zai Huang at 9.21% with a 3.78% increase - Dong E E Jiao at 6.18% with a 0.73% increase [2]. Group 2: Technological Advancements - The launch of the first "Traditional Chinese Medicine Brain-Machine Interface" equipment marks a significant technological advancement, aimed at treating neurological disorders [3]. - This technology integrates brain-machine interface with acupuncture, showcasing innovation in the field of traditional medicine [3]. Group 3: Policy Developments - The implementation of the "Drug Administration Law Implementation Regulations" emphasizes a review system for traditional Chinese medicine based on traditional theories, human experience, and clinical data [4]. - The regulations aim to ensure the safety and traceability of traditional Chinese medicine products, which may lead to industry consolidation and growth for leading companies [4]. Group 4: Investment Opportunities - Three main investment themes in the Chinese medicine sector are identified: 1. Price governance, focusing on competitive products and companies that can leverage price reductions for volume growth [5]. 2. Consumption recovery, driven by macroeconomic improvement and an aging population, benefiting companies with strong brand and product advantages [7]. 3. State-owned enterprise reform, which may enhance performance through efficiency improvements in state-controlled companies [8]. Group 5: Market Activity - The Chinese medicine ETF (560080) has seen increased trading activity, with a transaction volume nearing 1 billion yuan and significant capital inflow over recent days [6].

Group 1 - The acquisition of Jiatang by Tongrentang Group aims to create a complete closed-loop pharmaceutical industry chain covering herbal planting, drug production, terminal distribution, and medical services, but its effectiveness in alleviating the "private label" pain remains to be seen [1][7] - On February 3, Jiatang announced that its shareholders, Everbright Industrial and Everbright Health, signed a share transfer agreement with Tongrentang Group, transferring a total of 83.05 million shares for 1.461 billion yuan [3] - Following the transaction, Tongrentang Group will become the controlling shareholder of Jiatang with a 28.48% stake, and the actual controller will change to the State-owned Assets Supervision and Administration Commission of Beijing [3][4] Group 2 - Jiatang has faced financial pressure, with revenue figures from 2020 to 2024 showing a decline in net profit, particularly a drop to 161 million yuan in 2024, marking a ten-year low [5] - For the first three quarters of 2025, Jiatang reported a revenue of 14.46 billion yuan, a year-on-year decrease of 21.8%, and a net profit of 141 million yuan, down 38.81% year-on-year [6] - Tongrentang, founded in 1669, currently has multiple listed companies and is actively pursuing the listing of Tongrentang Medical and Health, which could enhance its capital presence [7] Group 3 - The merger is viewed as a "strong union," combining Tongrentang's brand strength and product resources with Jiatang's extensive distribution network, potentially allowing Jiatang to return to its core pharmaceutical operations [7] - Tongrentang has recently faced a trust crisis due to a product quality issue, which has negatively impacted its stock price and overall performance, with a revenue decline of 3.70% and a net profit drop of 12.78% in the first three quarters of 2025 [8]